Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug
- 206 Downloads
Glucocorticoid, such as dexamethasone (Dex) is often used along with chemotherapy to antagonize side effects of chemotherapy. However, sustained use of Dex frequently develops drug resistance in patients. As a strategy to re-induce drug sensitivity, we planned to modify Dex by chemically conjugating it with twin ten carbon aliphatic chain containing cationic lipid. The resultant molecule, DX10, inhibited STAT3 activation through lowering the production of IL-6. To enhance the STAT3 inhibitory effect of DX10, we used WP (a commercially available STAT3 inhibitor) along with DX10. Combination treatment of both significantly inhibited STAT3 activation when compared to either of the individual treatment. The effect of DX10, either in combination or alone, was mediated through glucocorticoid receptor (GR), thereby repurposing the role of GR in the context of p-STAT3 inhibition-mediated cancer treatment. Cellular viability study proved the synergistic effect of WP and DX10. Further, combination treatment led to induction of early stage of apoptosis and cell cycle arrest. In vivo melanoma tumor regression study confirmed the enhanced anti-tumor activity of co-treatment over individual treatment of DX10 or WP. Thus, together our result demonstrates that DX10 may be used in combination therapy with STAT3 inhibitor like WP for combating cancer with constitutively active STAT3.
KeywordsGlucocorticoid receptor Dexamethasone derivative STAT3 inhibition Drug sensitization Repurposing WP1066
SS and SKM thank Council of Scientific and Industrial Research (CSIR), Government of India, New Delhi for their doctoral research fellowships. RB acknowledges financial assistance from CSIR Network Project Grant [CSC0302, BSC0123], Govt. of India.
Compliance with ethical standards
Conflict of interest
The authors declare that there is no conflict of interest.
- 6.Rocha LC, Sherman CA, Brescia FJ, Brunson CY, Green MR (2001) Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer. Oncology 15:46–51Google Scholar
- 18.Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM et al (2006) Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91:1498–1505PubMedGoogle Scholar
- 25.Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W et al (2008) A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14:5759–5768CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Takeda T, Kurachi H, Yamamoto T, Nishio Y, Nakatsuji Y, Morishige KI et al (1998) Crosstalk between the interleukin-6 (IL-6)-JAK-STAT and the glucocorticoid-nuclear receptor pathway: synergistic activation of IL-6 response element by IL-6 and glucocorticoid. J Endocrinol 159:323–330CrossRefPubMedGoogle Scholar
- 28.Verhoog NJ, Du Toit A, Avenant C, Hapgood JP (2011) Glucocorticoid-independent repression of tumor necrosis factor (TNF) alpha-stimulated interleukin (IL)-6 expression by the glucocorticoid receptor: a potential mechanism for protection against an excessive inflammatory response. J Biol Chem 286:19297–19310CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Obrador E, Valles SL, Benlloch M, Sirerol JA, Pellicer JA, Alcácer J, Coronado JAF, Estrela JM (2014) Glucocorticoid receptor knockdown decreases the antioxidant protection of B16 melanoma cells: an endocrine system-related mechanism that compromises metastatic cell resistance to vascular endothelium- induced tumor cytotoxicity. PLoS ONE 9(5):e96466CrossRefPubMedPubMedCentralGoogle Scholar